Published in Nat Rev Cancer on February 01, 2010
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid Cancer | NCT02363647
Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol (2011) 5.65
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol (2011) 3.72
Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol (2012) 3.65
Automated design of ligands to polypharmacological profiles. Nature (2012) 3.54
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature (2011) 3.18
Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer (2011) 2.34
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature (2012) 2.33
Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput Biol (2011) 2.31
Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol (2013) 2.01
Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets (2010) 1.76
Chromosomal instability and aneuploidy in cancer: from yeast to man. EMBO Rep (2012) 1.51
Activation pathway of Src kinase reveals intermediate states as targets for drug design. Nat Commun (2014) 1.48
Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release. J Cell Mol Med (2012) 1.40
Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest (2017) 1.39
What is the likelihood of an active compound to be promiscuous? Systematic assessment of compound promiscuity on the basis of PubChem confirmatory bioassay data. AAPS J (2013) 1.35
Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs (2011) 1.29
Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. Mol Cell (2011) 1.28
How chemoproteomics can enable drug discovery and development. Chem Biol (2012) 1.27
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov (2014) 1.26
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs (2014) 1.26
SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov (2014) 1.25
Structure-based systems biology for analyzing off-target binding. Curr Opin Struct Biol (2011) 1.25
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene (2013) 1.23
Outlier kinase expression by RNA sequencing as targets for precision therapy. Cancer Discov (2013) 1.13
Phosphoproteomics in cancer. Mol Oncol (2010) 1.12
High-resolution view of compound promiscuity. F1000Res (2013) 1.11
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem Biol (2012) 1.10
mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J Biol Chem (2010) 1.09
Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. Oncotarget (2014) 1.07
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer (2011) 1.07
A coiled-coil enabled split-luciferase three-hybrid system: applied toward profiling inhibitors of protein kinases. J Am Chem Soc (2010) 1.05
ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One (2011) 1.05
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J Med Chem (2013) 1.04
ChemProt: a disease chemical biology database. Nucleic Acids Res (2010) 1.03
In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc Natl Acad Sci U S A (2014) 1.02
Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell (2011) 1.02
Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.00
Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways. PLoS Comput Biol (2013) 1.00
Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics (2012) 0.99
Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PLoS One (2013) 0.99
Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel) (2015) 0.99
Kinome-wide activity modeling from diverse public high-quality data sets. J Chem Inf Model (2013) 0.98
Prediction of chemical-protein interactions network with weighted network-based inference method. PLoS One (2012) 0.97
Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing. Nat Chem Biol (2011) 0.97
Systematic mining of analog series with related core structures in multi-target activity space. J Comput Aided Mol Des (2013) 0.97
Quantitative phosphoproteome analysis of Bacillus subtilis reveals novel substrates of the kinase PrkC and phosphatase PrpC. Mol Cell Proteomics (2014) 0.94
Selective killing of p53-deficient cancer cells by SP600125. EMBO Mol Med (2012) 0.94
Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth. ACS Chem Biol (2015) 0.93
The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J Virol (2013) 0.92
Human VRK2 modulates apoptosis by interaction with Bcl-xL and regulation of BAX gene expression. Cell Death Dis (2013) 0.92
The next steps in next-gen sequencing of cancer genomes. J Clin Invest (2015) 0.91
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep (2013) 0.91
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology (2015) 0.89
Monitoring drug promiscuity over time. F1000Res (2014) 0.88
Determining the Degree of Promiscuity of Extensively Assayed Compounds. PLoS One (2016) 0.88
Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int J Cancer (2013) 0.87
Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen. J Med Chem (2012) 0.87
Differential inhibitor sensitivity between human kinases VRK1 and VRK2. PLoS One (2011) 0.87
A fluorescent reporter of the phosphorylation status of the substrate protein STAT3. Angew Chem Int Ed Engl (2011) 0.87
Local cAMP signaling in disease at a glance. J Cell Sci (2013) 0.87
Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1. PLoS One (2011) 0.86
The energy landscape analysis of cancer mutations in protein kinases. PLoS One (2011) 0.86
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor. Bioorg Med Chem (2015) 0.85
Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS One (2014) 0.85
A theoretical entropy score as a single value to express inhibitor selectivity. BMC Bioinformatics (2011) 0.85
Phosphatase-coupled universal kinase assay and kinetics for first-order-rate coupling reaction. PLoS One (2011) 0.85
Entering the 'big data' era in medicinal chemistry: molecular promiscuity analysis revisited. Future Sci OA (2017) 0.85
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cell Oncol (Dordr) (2015) 0.84
Differential expression of miR-1, a putative tumor suppressing microRNA, in cancer resistant and cancer susceptible mice. PeerJ (2013) 0.84
Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach. Genome Med (2014) 0.84
Target essentiality and centrality characterize drug side effects. PLoS Comput Biol (2013) 0.83
Global survey of the immunomodulatory potential of common drugs. Nat Chem Biol (2017) 0.83
Chemical genetics of rapamycin-insensitive TORC2 in S. cerevisiae. Cell Rep (2013) 0.83
Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity. Proc Natl Acad Sci U S A (2015) 0.83
Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. Transl Oncol (2011) 0.83
The Basic Biology of PP2A in Hematologic Cells and Malignancies. Front Oncol (2014) 0.83
Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation. Nat Chem Biol (2016) 0.82
In Silico target fishing: addressing a "Big Data" problem by ligand-based similarity rankings with data fusion. J Cheminform (2014) 0.81
P6981, an arylstibonic acid, is a novel low nanomolar inhibitor of cAMP response element-binding protein binding to DNA. Mol Pharmacol (2012) 0.81
Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy. ACS Chem Biol (2015) 0.81
Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol (2013) 0.81
Systems biology network-based discovery of a small molecule activator BL-AD008 targeting AMPK/ZIPK and inducing apoptosis in cervical cancer. Oncotarget (2015) 0.81
Pathway-based screening strategy for multitarget inhibitors of diverse proteins in metabolic pathways. PLoS Comput Biol (2013) 0.81
Shedding light on local kinase activation. BMC Biol (2012) 0.81
CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. Elife (2017) 0.81
Comparison of ultra-fast 2D and 3D ligand and target descriptors for side effect prediction and network analysis in polypharmacology. Br J Pharmacol (2013) 0.81
Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response. Cancer Biol Ther (2012) 0.80
Drug combination therapy increases successful drug repositioning. Drug Discov Today (2016) 0.80
Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention. Mol Pharm (2014) 0.80
Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo. Invest New Drugs (2010) 0.80
Are phylogenetic trees suitable for chemogenomics analyses of bioactivity data sets: the importance of shared active compounds and choosing a suitable data embedding method, as exemplified on Kinases. J Cheminform (2013) 0.79
Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res (2016) 0.79
Profiling small molecule inhibitors against helix-receptor interactions: the Bcl-2 family inhibitor BH3I-1 potently inhibits p53/hDM2. Chem Commun (Camb) (2010) 0.79
A novel drug discovery strategy: mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways. Oncotarget (2014) 0.79
Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives. Oncol Rev (2013) 0.79
Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2. Bioorg Med Chem (2012) 0.78
Computational polypharmacology comes of age. Front Pharmacol (2015) 0.78
Exploring compound promiscuity patterns and multi-target activity spaces. Comput Struct Biotechnol J (2014) 0.78
Computational Modeling of Kinase Inhibitor Selectivity. ACS Med Chem Lett (2010) 0.78
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
The protein kinase complement of the human genome. Science (2002) 35.36
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J (2000) 22.23
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
The selectivity of protein kinase inhibitors: a further update. Biochem J (2007) 15.73
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Cetuximab for the treatment of colorectal cancer. N Engl J Med (2007) 13.39
Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med (2007) 12.73
A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol (2005) 12.22
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (1994) 10.34
EGFR antagonists in cancer treatment. N Engl J Med (2008) 9.68
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol (2008) 8.51
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 8.34
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell (2009) 6.97
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell (2009) 6.02
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature (2009) 4.93
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest (2007) 4.07
Features of selective kinase inhibitors. Chem Biol (2005) 4.07
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res (2008) 3.70
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell (2008) 3.68
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology (2004) 3.61
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007) 3.26
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A (2007) 3.21
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res (2009) 3.21
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res (2001) 3.18
Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer (2001) 2.82
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res (2007) 2.62
Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol (2001) 2.59
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood (2006) 2.50
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol (2004) 2.32
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther (2005) 2.15
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol (2002) 2.14
Chemical genetics: where genetics and pharmacology meet. Cell (2007) 2.09
Can we rationally design promiscuous drugs? Curr Opin Struct Biol (2006) 2.06
Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc Natl Acad Sci U S A (2008) 1.95
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J Med Chem (2008) 1.74
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A (2008) 1.71
Cancer: mixing cocktails. Nature (2007) 1.57
Target identification in chemical genetics: the (often) missing link. Chem Biol (2004) 1.47
Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet (2002) 1.40
Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res (1997) 1.36
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res (2008) 1.35
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res (2005) 1.31
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res (2001) 1.26
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res (2006) 1.26
Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells. Proc Natl Acad Sci U S A (2008) 1.17
Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther (2002) 1.11
Challenges and opportunities in defining the essential cancer kinome. Sci Signal (2009) 1.05
Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov Today (2009) 1.05
RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene (2006) 0.93
For investigational targeted drugs, combination trials pose challenges. J Natl Cancer Inst (2003) 0.80
Is the gefitinib plus trastuzumab combination feasible in breast cancer patients? Ann Oncol (2005) 0.80
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
IRE1 signaling affects cell fate during the unfolded protein response. Science (2007) 9.01
Targets of the cyclin-dependent kinase Cdk1. Nature (2003) 8.05
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A (2008) 5.97
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 5.53
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res (2006) 5.21
Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 4.91
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature (2013) 4.43
The site-specific installation of methyl-lysine analogs into recombinant histones. Cell (2007) 4.22
Features of selective kinase inhibitors. Chem Biol (2005) 4.07
Rewiring of genetic networks in response to DNA damage. Science (2010) 4.03
The unfolded protein response signals through high-order assembly of Ire1. Nature (2008) 3.87
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell (2010) 3.79
The Ipl1-Aurora protein kinase activates the spindle checkpoint by creating unattached kinetochores. Nat Cell Biol (2005) 3.61
Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A (2007) 3.48
Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal (2010) 3.35
A chemical-genetic strategy implicates myosin-1c in adaptation by hair cells. Cell (2002) 3.34
Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell (2006) 3.32
Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science (2010) 3.20
Functional organization of the S. cerevisiae phosphorylation network. Cell (2009) 3.15
The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell (2011) 2.99
A chemical-genetic approach to studying neurotrophin signaling. Neuron (2005) 2.93
Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science (2009) 2.82
Control of landmark events in meiosis by the CDK Cdc28 and the meiosis-specific kinase Ime2. Genes Dev (2003) 2.79
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
The F box protein Dsg1/Mdm30 is a transcriptional coactivator that stimulates Gal4 turnover and cotranscriptional mRNA processing. Cell (2005) 2.75
Chemical genetic analysis of Apg1 reveals a non-kinase role in the induction of autophagy. Mol Biol Cell (2003) 2.72
Evolution of phosphoregulation: comparison of phosphorylation patterns across yeast species. PLoS Biol (2009) 2.67
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res (2007) 2.62
Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates. Proc Natl Acad Sci U S A (2008) 2.53
A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases. Nat Methods (2005) 2.47
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med (2010) 2.42
A semisynthetic epitope for kinase substrates. Nat Methods (2007) 2.40
Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci U S A (2007) 2.37
Phosphoproteomic analysis reveals interconnected system-wide responses to perturbations of kinases and phosphatases in yeast. Sci Signal (2010) 2.36
Discovery-based science education: functional genomic dissection in Drosophila by undergraduate researchers. PLoS Biol (2005) 2.33
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature (2012) 2.33
Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J (2006) 2.33
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell (2008) 2.32
JNK2 is a positive regulator of the cJun transcription factor. Mol Cell (2006) 2.32
Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol (2007) 2.31
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell (2013) 2.28
Two cyclin-dependent kinases promote RNA polymerase II transcription and formation of the scaffold complex. Mol Cell Biol (2004) 2.26
Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature (2010) 2.25
Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell (2007) 2.22
An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol (2008) 2.21
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res (2008) 2.20
Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood (2003) 2.17
Nuclear HuR accumulation through phosphorylation by Cdk1. Genes Dev (2008) 2.14
An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol (2005) 2.11
To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front. J Cell Biol (2006) 2.10
Chemical genetics: where genetics and pharmacology meet. Cell (2007) 2.09
Arabidopsis MAP kinase 4 regulates salicylic acid- and jasmonic acid/ethylene-dependent responses via EDS1 and PAD4. Plant J (2006) 2.07
A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature (2011) 2.07
Mps1 directs the assembly of Cdc20 inhibitory complexes during interphase and mitosis to control M phase timing and spindle checkpoint signaling. J Cell Biol (2010) 2.07
Tuning the activation threshold of a kinase network by nested feedback loops. Science (2009) 2.03
Complementary detection of prostate-specific antigen using In2O3 nanowires and carbon nanotubes. J Am Chem Soc (2005) 1.97
A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci U S A (2007) 1.97
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J (2008) 1.96
Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. Proc Natl Acad Sci U S A (2003) 1.93
The cyclin-dependent kinase (CDK) family member PNQALRE/CCRK supports cell proliferation but has no intrinsic CDK-activating kinase (CAK) activity. Cell Cycle (2006) 1.90
Hierarchical modularity and the evolution of genetic interactomes across species. Mol Cell (2012) 1.88
A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1. Cell (2013) 1.84
Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol (2003) 1.82
Phosphorylation of the transcription elongation factor Spt5 by yeast Bur1 kinase stimulates recruitment of the PAF complex. Mol Cell Biol (2009) 1.82
The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu Rev Biochem (2011) 1.80
Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol (2009) 1.78
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem (2004) 1.77
Maintenance of hormone-sensitive phosphoinositide pools in the plasma membrane requires phosphatidylinositol 4-kinase IIIalpha. Mol Biol Cell (2007) 1.77
Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol (2012) 1.74
The effect of H3K79 dimethylation and H4K20 trimethylation on nucleosome and chromatin structure. Nat Struct Mol Biol (2008) 1.73
Cdk1-dependent phosphorylation of Cdc13 coordinates telomere elongation during cell-cycle progression. Cell (2009) 1.72
Chemical inhibition of the TFIIH-associated kinase Cdk7/Kin28 does not impair global mRNA synthesis. Proc Natl Acad Sci U S A (2007) 1.71
Cdc28-Clb5 (CDK-S) and Cdc7-Dbf4 (DDK) collaborate to initiate meiotic recombination in yeast. Genes Dev (2008) 1.68
Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J Ind Microbiol Biotechnol (2012) 1.67
Suppression of p53-dependent senescence by the JNK signal transduction pathway. Proc Natl Acad Sci U S A (2007) 1.67
Bio-orthogonal affinity purification of direct kinase substrates. J Am Chem Soc (2005) 1.67
The protein kinase Kin4 inhibits exit from mitosis in response to spindle position defects. Mol Cell (2005) 1.67
TFIIH and P-TEFb coordinate transcription with capping enzyme recruitment at specific genes in fission yeast. Mol Cell (2009) 1.66
EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal (2009) 1.66
Combining chemical genetics and proteomics to identify protein kinase substrates. Proc Natl Acad Sci U S A (2005) 1.63
Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs. J Biol Chem (2003) 1.60
Phosphospecific proteolysis for mapping sites of protein phosphorylation. Nat Biotechnol (2003) 1.60
Dissecting the Engrailed homeodomain-DNA interaction by phage-displayed shotgun scanning. Chem Biol (2004) 1.56
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest (2008) 1.56
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A (2013) 1.53
Phosphatidylinositol 4-kinase IIIbeta regulates the transport of ceramide between the endoplasmic reticulum and Golgi. J Biol Chem (2006) 1.52
The emerging power of chemical genetics. Curr Opin Cell Biol (2002) 1.52
Ultrasonography in community emergency departments in the United States: access to ultrasonography performed by consultants and status of emergency physician-performed ultrasonography. Ann Emerg Med (2005) 1.52
Regulation of meiotic recombination via Mek1-mediated Rad54 phosphorylation. Mol Cell (2009) 1.51